Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy

The programmed cell death 1 (PD-1) inhibitor - camrelizumab - is a promising agent for the treatment of several malignancies. Secondary hypophysitis has been reported in patients treated with the other PD-1 inhibitors such as nivolumab and pembrolizumab. However, camrelizumab-related hypophysitis ha...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of cancer research and therapeutics 2022-09, Vol.18 (5), p.1440-1443
Hauptverfasser:	Han, Xiaoying, Meng, Min, Zhang, Tiehong, Wang, Jiao, Huang, Guanghui, Ni, Yang, Li, Wenhong, Dai, Jianjian, Yang, Xia, Ye, Xin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse and side effects Cancer Case studies Causes of Cell death Complications and side effects Drug therapy Drugs Inhibitor drugs Kidney cancer Lung cancer Lung cancer, Non-small cell Monoclonal antibodies Pituitary diseases Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!